Contact Information
Sumanta Kumar Pal, M.D.
  • Assistant Professor, Department of Medical Oncology & Therapeutics Research
  • Co-director, Kidney Cancer Program

Primary Specialties

Languages Spoken
  • Spanish


Sumanta Kumar Pal, M.D., is an assistant professor in the Department of Medical Oncology & Therapeutics Research and co-director of the Kidney Cancer Program at City of Hope. Having been appointed to the faculty for just over four years, Dr. Pal has been extremely productive, publishing more than 80 manuscripts in peer-reviewed journals.  He has presented his work in multiple international meetings.
Dr. Pal began his college career at the age of 13 through the California State University, Los Angeles Early Entrance Program. He began medical school at the age of 17 at the University of California, Los Angeles (UCLA), where he developed an immediate interest in cancer research. Working in the laboratory of Dennis Slamon, M.D., Ph.D., Dr. Pal examined the breast cancer drug trastuzumab, performing laboratory-based studies to elucidate mechanisms of resistance to the agent. He continued this work during the course of his residency training at UCLA.
After completing his residency, Dr. Pal transitioned to City of Hope where he trained under Robert Figlin, M.D., developing clinical trials and translational studies for genitourinary cancer, principally in the domain of renal cell carcinoma and prostate cancer. He has garnered numerous awards to support his work, including grants from the California Breast Cancer Research Program, the National Comprehensive Cancer Network and the National Institutes of Health.  He recently received a Young Investigator Award from the Kidney Cancer Association to recognize his outstanding research in this domain, and further received the 2012 Charles A. Coltman Translational Research Award from the Southwest Oncology Group to support his work in bladder cancer. 
Dr. Pal’s vision is to take discoveries made in the laboratory and translate these findings as quickly and efficiently as possible into tangible benefits for patients.

Professional Experience

  • 2009 - present, Assistant Professor, Medical Oncology & Therapeutics Research, City of Hope, Duarte, CA
  • 2009 - present, Co-director, Kidney Cancers Program, City of Hope, Duarte, CA

Education and Training

  • 2003, UCLA School of Medicine, M.D.
  • 1998, California State University, Los Angeles Early Entrance Program, College in lieu of high school (program initiated at age 13); Magna Cum Laude, B.Sc.
  • 2006 - 2009, Fellowship in Hematology/Oncology, City of Hope/Harbor-UCLA Medical Center, Los Angeles, CA
  • 2003 - 2006, Residency in Internal Medicine, UCLA Medical Center, Los Angeles, CA

Honors and Awards

  • 2012, Southwest Oncology Group Coltman Translational Investigator Award
  • 2011, Tower Cancer Research Foundation Award
  • 2009, California Breast Cancer Research Program Junior IDEA Grant
  • 2008, Amgen Fellowship Award
  • 2008, ASCO Merit Award, Breast Cancer Symposium
  • 2008, First Place (Clinical Research), City of Hope First Annual Collaboration Meeting
  • 2007, National Comprehensive Cancer Network (NCCN) Fellowship Award
  • 2007, American Medical Association Seed Grant Award
  • 2006, First Place (Poster Presentation), City of Hope First Annual Collaboration Meeting
  • 2006, Commendation for Excellence in Medical Student Teaching
  • 2005, Outstanding Research Award, American College of Physicians


2006-present, American Society of Clinical Oncology (ASCO) (2006- present)
National Comprehensive Cancer Network Bladder Cancer Committee (2010-present)
HER2-Positive Breast Cancer Committee, ASCO (2012-2013)
Genitourinary Cancers Committee, ASCO (2013-present )


1. Pal SK, Figlin RA. Ramucirumab in metastatic renal cell carcinoma: The beginning or the end? Cancer. 2014 Feb 27. PubMed PMID: 24577887. Epub 2014/03/01.

2. Pal SK, Ruel N, Vogelzang N, Chang M, Wilson TG, Jones JO, Yuh B. Preoperative Androgen Deprivation Therapy for Localized Prostate Cancer: Delayed Biochemical Recurrence in High-Risk Disease. Clin Genitourin Cancer. 2013 Nov 12. [Epub ahead of print] (PMID: 24342128)

3. Dorff TB, Pal SK, Quinn DI. Novel tyrosine kinase inhibitors for renal cell carcinoma. Expert Rev Clin Pharmacol. 2014 Jan;7(1):67-73. (PMID: 24308791)

4. Schutz FA, Xie W, Donskov F, Sircar M, McDermott DF, Rini BI, Agarwal N, Pal SK, Srinivas S, Kollmannsberger C, North SA, Wood LA, Vaishampayan U, Tan MH, Mackenzie MJ, Lee JL, Rha SY, Yuasa T, Heng DY, Choueiri TK.  The Impact of Low Serum Sodium on Treatment Outcome of Targeted Therapy in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Cancer Database Consortium.  Eur Urol. 2013 Oct 26. [Epub ahead of print] (PMID: 24184025)

5. Schroeder A, Herrmann A, Cherryholmes G, Kowolik C, Buettner R, Pal S, Yu H, Müller-Newen G, Jove R. Loss of Androgen Receptor Expression Promotes a Stem-like Cell Phenotype in Prostate Cancer through STAT3 Signaling. Cancer Res. 2014 Feb 7. [Epub ahead of print] (PMID:24177177)

6. Gao C, Kozlowska A, Nechaev S, Li H, Zhang Q, Hossain DM, Kowolik CM, Chu P, Swiderski P, Diamond DJ, Pal SK, Raubitschek A, Kortylewski M. TLR9 signaling in the tumor microenvironment initiates cancer recurrence after radiation therapy. Cancer Res. 2013 Oct 23. [Epub ahead of print] (PMID: 24154870)

7. Loscalzo M, Clark K, Pal S, Pirl WF. Role of biopsychosocial screening in cancer care. Cancer journal 2013 Sep-Oct;19(5):414-20. (PMID: 24051615)

8. McKay RR, Kroeger N, Xie W, Lee JL, Knox JJ, Bjarnason GA, Mackenzie MJ, Wood L, Srinivas S, Vaishampayan UN, Rha SY, Pal SK, Donskov F, Tantravahi SK, Rini BI, Heng DY, Choueiri TK. Impact of Bone and Liver Metastases on Patients with Renal Cell Carcinoma Treated with Targeted Therapy. European urology 2013 Aug 15. [Epub ahead of print] (PMID: 23962746)

9. Kroeger N, Choueiri TK, Lee JL, Bjarnason GA, Knox JJ, Mackenzie MJ, Wood L, Srinivas S, Vaishamayan UN, Rha SY, Pal SK, Yuasa T, Donskov F, Agarwal N, Tan MH, Bamias A, Kollmannsberger CK, North SA, Rini BI, Heng DY. Survival Outcome and Treatment Response of Patients with Late Relapse from Renal Cell Carcinoma in the Era of Targeted Therapy. European urology 2013 Jul 30. [Epub ahead of print] (PMID: 23916693)

10. Pal SK, Hu A, Figlin RA. A new age for vaccine therapy in renal cell carcinoma. Cancer journal 2013 Jul-Aug;19(4):365-70.

11. Pal SK, Milowsky MI, Plimack ER. Optimizing systemic therapy for bladder cancer. Journal of the National Comprehensive Cancer Network: JNCCN 2013 Jul 1;11(7):793-804.

12. Yang C, Lee H, Pal S, Jove V, Deng J, Zhang W, Hoon DS, Wakabayashi M, Forman S, Yu H. B Cells Promote Tumor Progression via STAT3 Regulated-Angiogenesis. PLoS One 2013;8(5):e64159. (PMID: 23734190)

13. Zhang W, Pal SK, Liu X, Yang C, Allahabadi S, Bhanji S, Figlin RA, Yu H, Reckamp KL. Myeloid clusters are associated with a pro-metastatic environment and poor prognosis in smoking-related early stage non-small cell lung cancer. PLoS One 2013;8(5):e65121. (PMID: 23717691)

14. Kroeger N, Xie W, Lee JL, Bjarnason GA, Knox JJ, Mackenzie MJ, Wood L, Srinivas S, Vaishamayan UN, Rha SY, Pal SK, Yuasa T, Donskov F, Agarwal N, Kollmannsberger CK, Tan MH, North SA, Rini BI, Choueiri TK, Heng DY. Metastatic non-clear cell renal cell carcinoma treated with targeted therapy agents: Characterization of survival outcome and application of the international mRCC database consortium criteria. Cancer 2013 May 21. (PMID: 2369129)

15. Clark PE, Spiess PE, Agarwal N, Biagioli MC, Eisenberger MA, Greenberg RE, Herr HW, Inman BA, Kuban DA, Kuzel TM, Lele SM, Michalski J, Pagliaro L, Pal SK, Patterson A, Plimack ER, Pohar KS, Porter MP, Richie JP, Sexton WJ, Shipley WU, Small EJ, Trump DL, Wile G, Wilson TG, Dwyer M, Ho M. Penile cancer. Journal of the National Comprehensive Cancer Network : JNCCN 2013 May 1;11(5):594-615. (PMID: 23667209)

This is a partial listing of peer-reviewed publication for Dr. Pal. For full listing, please request CV.


  • City of Hope | Main Campus (Duarte)
    1500 East Duarte Road
    Duarte, CA 91010